Michael Pine

Chief Business Officer

As Chief Business Officer, Michael Pine draws on his more than 20 years of industry experience in business development & licensing, commercial, and financial functions to generate growth and drive strategy at Eyepoint Pharmaceuticals. Prior to joining EyePoint in 2022, Mr. Pine served as Senior Vice President of Business Development and Strategy at Medexus Pharmaceuticals, where he managed the company’s inorganic growth strategy, facilitated partnerships and acquisitions, and supported several transactions critical to the growth of the organization. He also previously held a variety of roles spanning business development, commercial, operational, and strategy functions at Lupin Pharmaceuticals, Aralez Pharmaceuticals, and Novartis Pharmaceuticals. Earlier in his career, Mr. Pine held similar roles at Kos Pharmaceuticals, Organon Biosciences, and Pfizer, and served as an Investment Banking Analyst at JP Morgan Chase. Mr. Pine holds a B.S. in Consumer Economics from Cornell University and an M.B.A. from Columbia Business School.